Kirkland worked for Regeneron between 2020 and 2022 to develop a global intellectual property strategy to protect its eye-disease medication known as EYLEA, a lawyer for the pharmaceutical company said in a court filing on Tuesday.
Now, Kirkland represents Novartis against claims that the company colluded to prevent Regeneron from offering EYLEA in the US. “It should be unthinkable that Kirkland would litigate this case against Regeneron,” Kimo Peluso, ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.